Abstract 3869
Background
Children and adolescents with cancer are at risk of experiencing distress in relation to their cancer diagnosis, treatment and treatment-related procedures. Complementary therapies such as reflexology may be used to help alleviate distressing symptoms; however, there is a dearth of research regarding the experience of reflexology from the perspective of children/adolescents with cancer and/or the parents/guardians of those who have received these treatments. Objective: To ascertain the perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage.
Methods
Children and adolescents aged between 7 and 18 years attending a national children’s hospital for cancer treatment were invited to participate in a randomised controlled trial using a Mixed Between Group Repeated Measures design following receipt of ethical approval from the hospital’s Research Ethics Committee. In total, 75 children/adolescents either consented or assented to take part in the study. Of these, 39 were randomized to the intervention group (reflexology) and 36 to the control group (non-specific foot massage). Semi-structured interviews were undertaken with parents/guardians using an interview guide. Interviews were analysed using Braun and Clarke’s (2006) thematic analysis.
Results
The overarching theme which emerged across the interviews was participants’ perceptions of the foot treatments in general as a means of supporting the child during treatment for cancer. This central theme is discussed under a number of subthemes, namely psychological wellbeing, perceived physiological impact, time and space, a safe relationship and service development.
Conclusions
The parents/guardians views regarding the foot treatments in general were consistently positive. The implications of the study findings and the future delivery of the complementary therapy service will be discussed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UCD.
Funding
Childhood Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract